Retracted: Antitumor effects of OSU‐2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma
Open Access
- 9 March 2011
- journal article
- retracted article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 53 (6), 1943-1958
- https://doi.org/10.1002/hep.24293
Abstract
Accumulating evidence suggests the therapeutic potential of the immunosuppressive agent FTY720 (fingolimod) in hepatocellular carcinoma (HCC). Based on our previous finding that FTY720 mediates apoptosis in HCC cells by activating reactive oxygen species (ROS)–protein kinase Cδ (PKCδ) signaling independent of effects on sphingosine‐1‐phosphate (S1P) receptors, we embarked on the pharmacological exploitation of FTY720 to develop a nonimmunosuppressive analogue with antitumor activity. This effort led to the development of OSU‐2S, which exhibits higher potency than FTY720 in suppressing HCC cell growth through PKCδ activation. In contrast to FTY720, OSU‐2S was not phosphorylated by sphingosine kinase 2 (SphK2) in vitro, and did not cause S1P1 receptor internalization in HCC cells or T lymphocyte homing in immunocompetent mice. Although devoid of S1P1 receptor activity, OSU‐2S exhibited higher in vitro antiproliferative efficacy relative to FTY720 against HCC cells without cytotoxicity in normal hepatocytes. Several lines of pharmacological and molecular genetic evidence indicate that ROS–PKCδ–caspase‐3 signaling underlies OSU‐2S–mediated antitumor effects, and that differences in the antitumor activity between FTY720 and OSU‐2S were attributable to SphK2‐mediated phosphorylation of FTY720, which represents a metabolic inactivation of its antitumor activity. Finally, OSU‐2S exhibited high in vivo potency in suppressing xenograft tumor growth in both ectopic and orthotopic models without overt toxicity. Conclusion: Using the molecular platform of FTY720, we developed OSU‐2S, a novel PKCδ‐targeted antitumor agent, which is devoid of S1P1 receptor activity and is highly effective in suppressing HCC tumor growth in vivo. These findings suggest that OSU‐2S has clinical value in therapeutic strategies for HCC and warrants continued investigation in this regard. (HEPATOLOGY 2011;)This publication has 28 references indexed in Scilit:
- PTEN‐ and p53‐mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude miceJournal of Cellular Biochemistry, 2010
- Tumor Grade-Dependent Alterations in the Protein Kinase C Isoform Pattern in Urinary Bladder CarcinomasEuropean Urology, 2004
- Reactive Oxygen Species Produced by NAD(P)H Oxidase Inhibit Apoptosis in Pancreatic Cancer CellsOnline Journal of Public Health Informatics, 2004
- FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injuryKidney International, 2004
- NOX enzymes and the biology of reactive oxygenNature Reviews Immunology, 2004
- The enigmatic protein kinase Cδ: complex roles in cell proliferation and survivalThe FASEB Journal, 2004
- Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease.2003
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsJournal of Biological Chemistry, 2002
- GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas.International Journal of Oncology, 2000
- The Balance between Sphingosine and Sphingosine-1-Phosphate Is Decisive for Mast Cell Activation after Fc∈ Receptor I TriggeringThe Journal of Experimental Medicine, 1999